CDNA
Price
$18.37
Change
+$0.28 (+1.55%)
Updated
Mar 11, 04:59 PM (EDT)
Capitalization
548.33M
50 days until earnings call
ZOMDF
Price
$0.03
Change
-$0.00 (-0.00%)
Updated
Mar 10 closing price
Capitalization
137.19M
Ad is loading...

CDNA vs ZOMDF

Header iconCDNA vs ZOMDF Comparison
Open Charts CDNA vs ZOMDFBanner chart's image
CareDx
Price$18.37
Change+$0.28 (+1.55%)
Volume$10.48K
Capitalization548.33M
Zomedica
Price$0.03
Change-$0.00 (-0.00%)
Volume$11.22M
Capitalization137.19M
CDNA vs ZOMDF Comparison Chart
Loading...
CDNA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
ZOMDF
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
CDNA vs. ZOMDF commentary
Mar 12, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is CDNA is a Hold and ZOMDF is a Hold.

Ad is loading...
COMPARISON
Comparison
Mar 12, 2025
Stock price -- (CDNA: $18.09 vs. ZOMDF: $0.03)
Brand notoriety: CDNA and ZOMDF are both not notable
Both companies represent the Medical Specialties industry
Current volume relative to the 65-day Moving Average: CDNA: 90% vs. ZOMDF: 134%
Market capitalization -- CDNA: $548.33M vs. ZOMDF: $137.19M
CDNA [@Medical Specialties] is valued at $548.33M. ZOMDF’s [@Medical Specialties] market capitalization is $137.19M. The market cap for tickers in the [@Medical Specialties] industry ranges from $3.82T to $0. The average market capitalization across the [@Medical Specialties] industry is $8.25B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

CDNA’s FA Score shows that 0 FA rating(s) are green whileZOMDF’s FA Score has 1 green FA rating(s).

  • CDNA’s FA Score: 0 green, 5 red.
  • ZOMDF’s FA Score: 1 green, 4 red.
According to our system of comparison, ZOMDF is a better buy in the long-term than CDNA.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

CDNA’s TA Score shows that 4 TA indicator(s) are bullish while ZOMDF’s TA Score has 4 bullish TA indicator(s).

  • CDNA’s TA Score: 4 bullish, 6 bearish.
  • ZOMDF’s TA Score: 4 bullish, 4 bearish.
According to our system of comparison, ZOMDF is a better buy in the short-term than CDNA.

Price Growth

CDNA (@Medical Specialties) experienced а -14.39% price change this week, while ZOMDF (@Medical Specialties) price change was -66.77% for the same time period.

The average weekly price growth across all stocks in the @Medical Specialties industry was -1.36%. For the same industry, the average monthly price growth was -7.35%, and the average quarterly price growth was -3.83%.

Reported Earning Dates

CDNA is expected to report earnings on May 01, 2025.

Industries' Descriptions

@Medical Specialties (-1.36% weekly)

Medical specialties are companies that make equipment used by the health care industry. Equipment manufactured and distributed by these companies include dialysis machines, blood analysis equipment, surgical equipment, dental instruments, and diagnostic tools, among other items. Large companies typically aim to produce and distribute high-quality products across a broad market spectrum. Smaller firms are more likely to specialize in a particular market segment. Due to the industry’s close association with medical treatments, they typically have low sensitivity to macroeconomic fluctuations. Within this industry, Abbott Laboratories, Medtronic Plc and Thermo Fisher Scientific Inc. are some of the companies with multi-billion market capitalizations in the U.S. stock markets.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
CDNA($548M) has a higher market cap than ZOMDF($137M). CDNA YTD gains are higher at: -15.507 vs. ZOMDF (-68.167). ZOMDF has higher annual earnings (EBITDA): -11.94M vs. CDNA (-84.92M). CDNA has more cash in the bank: 235M vs. ZOMDF (106M). ZOMDF has less debt than CDNA: ZOMDF (1.75M) vs CDNA (34.2M). CDNA has higher revenues than ZOMDF: CDNA (280M) vs ZOMDF (24M).
CDNAZOMDFCDNA / ZOMDF
Capitalization548M137M400%
EBITDA-84.92M-11.94M712%
Gain YTD-15.507-68.16723%
P/E RatioN/AN/A-
Revenue280M24M1,167%
Total Cash235M106M222%
Total Debt34.2M1.75M1,952%
FUNDAMENTALS RATINGS
CDNA vs ZOMDF: Fundamental Ratings
CDNA
ZOMDF
OUTLOOK RATING
1..100
6853
VALUATION
overvalued / fair valued / undervalued
1..100
96
Overvalued
23
Undervalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
9491
PRICE GROWTH RATING
1..100
9391
P/E GROWTH RATING
1..100
66100
SEASONALITY SCORE
1..100
n/an/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

ZOMDF's Valuation (23) in the Pharmaceuticals Major industry is significantly better than the same rating for CDNA (96) in the Medical Specialties industry. This means that ZOMDF’s stock grew significantly faster than CDNA’s over the last 12 months.

ZOMDF's Profit vs Risk Rating (100) in the Pharmaceuticals Major industry is in the same range as CDNA (100) in the Medical Specialties industry. This means that ZOMDF’s stock grew similarly to CDNA’s over the last 12 months.

ZOMDF's SMR Rating (91) in the Pharmaceuticals Major industry is in the same range as CDNA (94) in the Medical Specialties industry. This means that ZOMDF’s stock grew similarly to CDNA’s over the last 12 months.

ZOMDF's Price Growth Rating (91) in the Pharmaceuticals Major industry is in the same range as CDNA (93) in the Medical Specialties industry. This means that ZOMDF’s stock grew similarly to CDNA’s over the last 12 months.

CDNA's P/E Growth Rating (66) in the Medical Specialties industry is somewhat better than the same rating for ZOMDF (100) in the Pharmaceuticals Major industry. This means that CDNA’s stock grew somewhat faster than ZOMDF’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
CDNAZOMDF
RSI
ODDS (%)
Bullish Trend 2 days ago
88%
Bullish Trend 2 days ago
90%
Stochastic
ODDS (%)
Bullish Trend 2 days ago
82%
Bullish Trend 2 days ago
81%
Momentum
ODDS (%)
Bearish Trend 2 days ago
85%
Bearish Trend 2 days ago
79%
MACD
ODDS (%)
Bearish Trend 2 days ago
89%
Bearish Trend 2 days ago
89%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
85%
Bearish Trend 2 days ago
83%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
88%
Bearish Trend 2 days ago
79%
Advances
ODDS (%)
Bullish Trend 27 days ago
83%
Bullish Trend 20 days ago
82%
Declines
ODDS (%)
Bearish Trend 8 days ago
86%
Bearish Trend 5 days ago
83%
BollingerBands
ODDS (%)
Bullish Trend 2 days ago
85%
Bullish Trend 2 days ago
76%
Aroon
ODDS (%)
N/A
Bearish Trend 2 days ago
77%
View a ticker or compare two or three
Ad is loading...
CDNA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
ZOMDF
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
PIOTX22.61N/A
N/A
Pioneer Core Equity A
GPTUX13.01N/A
N/A
GuidePath® Tactical Allocation Svc
SCURX29.75N/A
N/A
Hartford Schroders US Small Cap Opps SDR
TEGRX26.90N/A
N/A
Templeton Growth R
CDGRX11.94N/A
N/A
Copeland Dividend Growth Fund Class A

CDNA and

Correlation & Price change

A.I.dvisor indicates that over the last year, CDNA has been loosely correlated with BLFS. These tickers have moved in lockstep 41% of the time. This A.I.-generated data suggests there is some statistical probability that if CDNA jumps, then BLFS could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To CDNA
1D Price
Change %
CDNA100%
-4.39%
BLFS - CDNA
41%
Loosely correlated
-3.72%
MTD - CDNA
41%
Loosely correlated
+0.22%
NTRA - CDNA
40%
Loosely correlated
-5.71%
VCYT - CDNA
39%
Loosely correlated
-5.09%
A - CDNA
34%
Loosely correlated
-3.79%
More

ZOMDF and

Correlation & Price change

A.I.dvisor indicates that over the last year, ZOMDF has been loosely correlated with SNDL. These tickers have moved in lockstep 38% of the time. This A.I.-generated data suggests there is some statistical probability that if ZOMDF jumps, then SNDL could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ZOMDF
1D Price
Change %
ZOMDF100%
+17.90%
SNDL - ZOMDF
38%
Loosely correlated
N/A
CDNA - ZOMDF
30%
Poorly correlated
+1.66%
EBS - ZOMDF
29%
Poorly correlated
-1.60%
ARAY - ZOMDF
29%
Poorly correlated
+1.12%
BNR - ZOMDF
28%
Poorly correlated
+4.08%
More